[go: up one dir, main page]

NO20062860L - Sammensetning og fremgangsmate for styrking av biologisk tilgjengelighet - Google Patents

Sammensetning og fremgangsmate for styrking av biologisk tilgjengelighet

Info

Publication number
NO20062860L
NO20062860L NO20062860A NO20062860A NO20062860L NO 20062860 L NO20062860 L NO 20062860L NO 20062860 A NO20062860 A NO 20062860A NO 20062860 A NO20062860 A NO 20062860A NO 20062860 L NO20062860 L NO 20062860L
Authority
NO
Norway
Prior art keywords
composition
enhancing bioavailability
bioavailability
enhancing
compositions
Prior art date
Application number
NO20062860A
Other languages
English (en)
Inventor
Liang-Chang Dong
Crystal Pollock-Dove
Jasmine Han
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO20062860L publication Critical patent/NO20062860L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En foreliggende oppfinnelsen vedrører sammensetninger og fremgangsmåter for økning av den biologiske tilgjengeligheten av fordelaktige midler med vannløselighet.
NO20062860A 2003-11-19 2006-06-19 Sammensetning og fremgangsmate for styrking av biologisk tilgjengelighet NO20062860L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52342103P 2003-11-19 2003-11-19
US10/984,401 US20050181049A1 (en) 2003-11-19 2004-11-09 Composition and method for enhancing bioavailability
PCT/US2004/037927 WO2005051358A1 (en) 2003-11-19 2004-11-12 Composition and method for enhancing bioavailability

Publications (1)

Publication Number Publication Date
NO20062860L true NO20062860L (no) 2006-08-17

Family

ID=34636467

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062860A NO20062860L (no) 2003-11-19 2006-06-19 Sammensetning og fremgangsmate for styrking av biologisk tilgjengelighet

Country Status (13)

Country Link
US (1) US20050181049A1 (no)
EP (1) EP1684726A4 (no)
JP (1) JP2007511608A (no)
KR (1) KR20060109934A (no)
AR (1) AR048017A1 (no)
AU (1) AU2004292415A1 (no)
CA (1) CA2546618A1 (no)
IL (1) IL175647A0 (no)
MX (1) MXPA06005630A (no)
NO (1) NO20062860L (no)
PE (1) PE20050584A1 (no)
TW (1) TW200529884A (no)
WO (1) WO2005051358A1 (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
CA2522708C (en) 2003-04-29 2013-05-28 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
ZA200704246B (en) * 2004-10-25 2009-09-30 Japan Tobacco Inc Solid medicinal preparation improved in solubility and stability and process for producing the same
MX2007004973A (es) * 2004-10-25 2007-06-14 Japan Tobacco Inc Formulacion solida con solubilidad y estabilidad mejoradas y metodo para producir la formulacion.
US20090208556A1 (en) 2004-10-29 2009-08-20 Regents Of The University Of California, The Porous photonic crystals for drug delivery to the eye
US20070009589A1 (en) * 2005-07-07 2007-01-11 Kandarapu Raghupathi Extended release compositions
US20070077309A1 (en) * 2005-09-30 2007-04-05 Wong Patrick S Banded controlled release nanoparticle active agent formulation dosage forms and methods
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007062228A1 (en) * 2005-11-28 2007-05-31 Orexigen Therapeutics, Inc. Sustained-release formulation of zonisamide
DK1973529T3 (da) * 2006-01-05 2011-09-12 Veloxis Pharmaceuticals As Fyldbar tablet, som er i stand til at falde hen
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR101971218B1 (ko) 2006-11-09 2019-08-27 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
DE102006054638B4 (de) * 2006-11-16 2014-12-04 Laburnum Gmbh Pharmazeutische Einzeldosisform
US8956602B2 (en) 2006-12-05 2015-02-17 Landec, Inc. Delivery of drugs
US8399007B2 (en) 2006-12-05 2013-03-19 Landec Corporation Method for formulating a controlled-release pharmaceutical formulation
GB0709541D0 (en) * 2007-05-17 2007-06-27 Jagotec Ag Pharmaceutical excipient
FR2918277B1 (fr) * 2007-07-06 2012-10-05 Coretecholding Nouveau procede de production de formes pharmaceutiques seches hydrodispersibles et les compositions hydrodispersibles ainsi obtenues
CA2905205A1 (en) 2007-07-10 2009-01-15 The Regents Of The University Of California A drug delivery device comprising a porous sio2 film or a sio2/polymer film
US20090035370A1 (en) * 2007-08-02 2009-02-05 Drugtech Corporation Dosage form and method of use
US8114883B2 (en) 2007-12-04 2012-02-14 Landec Corporation Polymer formulations for delivery of bioactive materials
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
EP2135601A1 (en) * 2008-06-20 2009-12-23 Capsulution Nanoscience AG Stabilization of amorphous drugs using sponge-like carrier matrices
ES2660674T3 (es) 2009-03-04 2018-03-23 Emplicure Ab Formulación resistente al abuso
CN105476951A (zh) 2009-05-04 2016-04-13 普西维达公司 多孔硅药物洗脱颗粒
JP5691051B2 (ja) 2009-05-08 2015-04-01 エンプリキュア・アクチエボラゲット ジオポリマー結合剤を含む持続薬物送達用組成物
WO2010144755A2 (en) * 2009-06-11 2010-12-16 Landec Corporation Compositions and methods for delivery of materials
EP2523557B1 (en) 2010-01-11 2019-09-25 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
DK2613784T3 (da) 2010-09-07 2018-01-29 Emplicure Ab Indretning til transdermal indgivelse af lægemiddel
JP6026424B2 (ja) 2010-11-01 2016-11-16 シヴィダ・ユーエス・インコーポレイテッドPsivida Us, Inc. 治療薬送達のための生物浸食性ケイ素ベースのデバイス
US9394369B2 (en) 2011-01-03 2016-07-19 The Regents Of The University Of California Luminescent porous silicon nanoparticles for targeted delivery and immunization
PT2858640T (pt) 2012-06-06 2020-06-30 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014151381A1 (en) 2013-03-15 2014-09-25 Psivida Us, Inc. Bioerodible silicon-based compositions for delivery of therapeutic agents
CA2990247C (en) 2015-07-09 2023-10-03 The Regents Of The University Of California Fusogenic liposome-coated porous silicon nanoparticles
EP3720434A4 (en) 2017-12-05 2021-09-01 Sunovion Pharmaceuticals Inc. NON-RACEMIC MIXTURES AND THEIR USE
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
PH12021553056A1 (en) 2019-06-04 2023-09-11 Sunovion Pharmaceuticals Inc Modified release formulations and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06511481A (ja) * 1991-07-05 1994-12-22 ユニバーシティ オブ ロチェスター 気泡を取り込む超微小非凝集多孔質粒子
JP2700141B2 (ja) * 1993-09-17 1998-01-19 富士化学工業株式会社 リン酸水素カルシウム及びその製法並びにそれを用いた賦形剤
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
SE512958C2 (sv) * 1998-04-30 2000-06-12 Triple Crown Ab Kolesterolsänkande komposition innehållande beta-sitosterol och/eller beta-sitostanol samt förfarande för dess framställning
JP4027535B2 (ja) * 1998-05-26 2007-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 脂溶性薬物を含有した粉末
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
JP2002532406A (ja) * 1998-12-17 2002-10-02 アルザ・コーポレーション 複合コーティングによる液体充填ゼラチンカプセルの放出制御システムへの変換
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
CN101961317A (zh) * 2001-07-06 2011-02-02 生命周期药物公司 受控制的凝聚
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet

Also Published As

Publication number Publication date
JP2007511608A (ja) 2007-05-10
EP1684726A1 (en) 2006-08-02
AR048017A1 (es) 2006-03-22
EP1684726A4 (en) 2007-10-03
MXPA06005630A (es) 2006-12-14
TW200529884A (en) 2005-09-16
CA2546618A1 (en) 2005-06-09
KR20060109934A (ko) 2006-10-23
US20050181049A1 (en) 2005-08-18
WO2005051358A8 (en) 2005-07-21
AU2004292415A1 (en) 2005-06-09
PE20050584A1 (es) 2005-08-15
IL175647A0 (en) 2006-09-05
WO2005051358A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
NO20062860L (no) Sammensetning og fremgangsmate for styrking av biologisk tilgjengelighet
CO5611137A2 (es) Composiciones de clorhidrato de naltrexona
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
MY153424A (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
BRPI0414599A (pt) pirrol-indóis substituìdos
ES2311803T3 (es) Composiciones embolicas de silicie pirogena.
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
DK1668001T3 (da) Substituerede heteroarylbenzofuransyrer
ZA200705177B (en) Lyophilization of virosomes
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
CY1109992T1 (el) Παραγωγα του αλφα-αμιναμιδιου χρησιμα ως αντιφλεγμονωδη μεσα
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
NO20071805L (no) Alkylidentetrahydronaftalenderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere.
ATE443044T1 (de) Tace inhibitoren
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
NO20062699L (no) Smelteblandingsdispergeringer
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
EP1590666A4 (en) COMPOSITIONS AND METHODS FOR REINFORCED APOPTOSIS
NO20060535L (no) Aztreonam-L-lysin og fremgangsmater for fremstilling av dette
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
EA200701852A1 (ru) Производные аминокислот

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application